Revvity, Inc. announced the launch of new highly characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative.
The Somatic Reference Samples (SRS) Initiative is a public-private partnership convened and led by MDIC to guide the development of reference samples that can be used to develop and validate NGS-based cancer diagnostics.
The new Mimix Geni reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line and engineered by Revvity to contain seven oncogenic mutations. Each mutation was carefully selected for its clinical significance by industry experts, including representatives from NIST, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and U.S. Food and Drug Administration (FDA). The reference standards have undergone extensive testing and validation by MDIC and NIST, with further validation by multiple labs planned soon.
"Through this collaboration, we’ve created novel reference standards that oncology diagnostics labs can really trust as a robust foundation for monitoring assay sensitivity, specificity, and reproducibility,” said Bryan Kipp, senior vice president, technology and licensing at Revvity. “Reliable reference standards with clinically relevant mutations support diagnostic labs in delivering more timely, precise and accurate results for cancer patients, which can provide a foundation for personalized treatment based on an individual’s specific cancer.”
Revvity will showcase its new Mimix Geni reference standards, along with other innovations, at the AMP annual meeting, November 11-15 in Boston, Massachusetts. For more information about Mimix Geni reference standards, visit their website.
Read Revvity's announcement here
